- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Intensity Therapeutics auf der H.C. Wainwright Konferenz: Daten, Liquidität und entscheidende Meilensteine | - | Investing.com Deutsch | ||
| 11.08. | Intensity Therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3 | 1 | Seeking Alpha | ||
| 11.08. | Intensity Therapeutics GAAP EPS of -$1.11 misses by $0.14 | 1 | Seeking Alpha | ||
| 11.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 685 | PR Newswire | Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026
... ► Artikel lesen | |
| 11.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.07. | Intensity Therapeutics resumes patient dosing in Swiss trial | 2 | Investing.com | ||
| 15.07. | Intensity Therapeutics setzt Patientendosierung in Schweizer Studie fort | - | Investing.com Deutsch | ||
| 15.07. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | 208 | PR Newswire | First patients dosed in Switzerland
SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a... ► Artikel lesen | |
| 08.07. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.07. | Intensity Therapeutics Inc.: Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 | 247 | PR Newswire | Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer
Over 200 patients enrolled in completed INT230-6 studies... ► Artikel lesen | |
| 16.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 660 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 330 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 341 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 345 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 628 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 460 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen | |
| 06.11.25 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 309 | PR Newswire | The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,55 | +3,80 % | Biontech mal wieder mit Plus - Gründer-Ehepaar vor Abschied | MAINZ (dpa-AFX) - Wenige Wochen vor dem angekündigten Abschied der Mitbegründer Ugur Sahin und Özlem Türeci hat Biontech einen Gewinn für das dritte Quartal gemeldet. Für die ersten neun Monate des... ► Artikel lesen | |
| NOVAVAX | 9,230 | +6,71 % | Novavax: Großaktionär verkauft - was jetzt wichtig ist | ||
| CRISPR THERAPEUTICS | 46,145 | +3,29 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition | ||
| INOVIO PHARMACEUTICALS | 1,422 | -3,85 % | Aktien New York: Nasdaq 100 rutscht vor Apple-Zahlen und Wahlen ins Minus | NEW YORK (dpa-AFX) - Die am Montag zunächst deutlich erholte US-Technologiebörse Nasdaq hat im Handelsverlauf merklich an Schwung verloren. Zuletzt notierte der Auswahlindex Nasdaq 100 0,36 Prozent... ► Artikel lesen | |
| INFLARX | 1,237 | -14,28 % | InflaRx rutscht ab: Warum die Kidney-Week-Fantasie verpufft | ||
| INTELLIA THERAPEUTICS | 10,780 | +1,70 % | Intellia schließt Rekrutierung für Phase-3-Studie zur ATTRv-PN-Therapie ab | ||
| EDITAS MEDICINE | 2,380 | +1,71 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,328 | +0,92 % | 3 Datenpakete vor dem ersten Patienten: Wie NurExone ExoPTEN auf die Klinik vorbereitet | ||
| GERON | 0,890 | +6,43 % | XFRA GON: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGERON CORP. (DEL.)... ► Artikel lesen | |
| IBIO | 0,733 | +0,34 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 7,490 | +0,94 % | ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ | First patients treated in Germany and Austria, with commercial support from Accord Healthcare
Treatment milestone follows European Commission's February 2026 conditional marketing authorization... ► Artikel lesen | |
| IMMATICS | 6,265 | -0,95 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| MYRIAD GENETICS | 5,352 | +0,26 % | Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln | WASHINGTON (dpa-AFX) - Laboratory services provider LabCorp Holdings Inc. (LH) announced on Tuesday that it has agreed to acquire the Prenatal Health testing business of molecular diagnostics... ► Artikel lesen | |
| MANNKIND | 3,473 | +4,20 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,872 | +2,68 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,200 (+6,08 %) liegt der Kurs bei 3,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.